Profiel
Christopher M.
Lindblom worked as Secretary, Treasurer, SVP-Finance & Administration at DNIB Unwind, Inc. from 2014 to 2016.
Prior to that, he was Chief Accounting Officer & Vice President-Finance at Infinity Pharmaceuticals, Inc. from 2006 to 2013.
He also worked as Treasurer & Vice President-Finance at Infinity Pharmaceuticals, Inc. in 2016 and at OvaScience, Inc. in 2014.
Lindblom holds an MBA from Boston College and an undergraduate degree from Syracuse University.
Eerdere bekende functies van Christopher M. Lindblom
| Bedrijven | Functie | Einde |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 25-07-2016 |
| DNIB UNWIND INC | Financieel Directeur/CFO | 21-03-2016 |
| INFINITY PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 12-04-2013 |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Financieel Directeur/CFO | 07-06-2013 |
Opleiding van Christopher M. Lindblom
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
DNIB Unwind, Inc.
DNIB Unwind, Inc. BiotechnologyHealth Technology Develops biopharmaceutical preparations | Health Technology |
Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Syracuse University
Syracuse University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Health Technology |
















